BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.
Productname
BPR1K871
HY-100865-1
By filling out this form, you are placing an order by e-mail. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Productname
BPR1K871
HY-100865-1
By filling out this form, you request a sample. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Are you looking for specific products, alternatives or documentation?